NovaVive Inc.

NovaVive Inc. is a private Canadian immunobiology company founded in July 2014 by Graeme McRae, the founder and Chairman Emeritus of Bioniche Life Sciences Inc. The company was established to introduce immunobiology-based technologies that are scientifically sound and address unmet veterinary medical needs. Its head office is located in Napanee, Ontario, Canada. In December 2014, NovaVive acquired the Mycobacterium Cell Wall Fraction (MCWF) technology platform that had formerly been part of Bioniche Animal Health. This technology was originally developed by Bioniche as part of its program to develop alternatives to antibiotics for animals. MCWF-based immunotherapies are used to treat cancer in animals and have also been modified to treat bladder cancer in humans. NovaVive's regulator-approved products are sold to veterinarians in the United States, Canada, Australia, New Zealand and the United Arab Emirates. Its product portfolio includes Amplimune®, an MCWF-based immunotherapy for cattle, and Settle®, an immunotherapy for equine endometritis. The company is managed by a group of experienced executives, many of whom previously worked at Bioniche and have collectively developed veterinary technologies that achieved large global market share. NovaVive continues to support and publish research on its immunotherapy platform. Recent studies have examined the use of Amplimune to reduce the likelihood of pneumonia in shipped calves and to prevent metritis in dairy cows, as well as the use of Settle to improve pregnancy rates in mares with endometritis.

NovaVive Inc. was founded in July 2014 as a private Canadian company by Graeme McRae, who is also the founder and Chairman Emeritus of Bioniche Life Sciences Inc. The company was created to introduce immunobiology-based technologies that are scientifically sound and address unmet veterinary medical needs. In December 2014, NovaVive acquired the Mycobacterium Cell Wall Fraction (MCWF) technology platform that was formerly part of Bioniche Animal Health. This technology was developed by Bioniche as part of its program to develop alternatives to antibiotics for animals. MCWF-based immunotherapies are also used to treat cancer in animals and have been modified to treat bladder cancer in humans. The company is managed by a group of experienced executives, many of whom previously worked at Bioniche. Collectively, they have successfully developed veterinary technologies that have taken large global market share in the face of rigorous competition. NovaVive's regulator-approved products are sold to veterinarians in the United States, Canada, Australia, New Zealand and the United Arab Emirates. Its head office is located in Napanee, Ontario, Canada. In March 2024, NovaVive announced that Settle®, its immunotherapy for equine endometritis, was now available in Canada, in addition to being sold in the USA, Australia, New Zealand and UAE. In April 2024, the company highlighted research showing that a single treatment of Amplimune 7 days after parturition may help prevent metritis in dairy cows. In March 2026, NovaVive reported that Settle® contributed to higher pregnancy rates in Australian horses with endometritis, based on a research abstract presented at the 2025 Bain Fallon Memorial Lectures.

• NovaVive Inc. founded as a private Canadian company by Graeme McRae.

• NovaVive acquired the Mycobacterium Cell Wall Fraction (MCWF) technology platform from Bioniche Animal Health.

• Settle® immunotherapy for equine endometritis became available in Canada.

• Research presented at the 2024 International Embryo Technology Society meeting showed Amplimune may help prevent metritis in dairy cows.

• Research presented at the 2025 Bain Fallon Memorial Lectures showed Settle® improved pregnancy outcomes in BHS-positive mares.

Developer of regulator-approved veterinary immunotherapies based on mycobacterium cell wall fraction (MCWF) technology, positioned as alternatives to antibiotics for animals.

• Amplimune®

  An MCWF-based immunotherapy for cattle. Research suggests it may reduce the likelihood of pneumonia in shipped calves and may help prevent metritis in dairy cows.

• Settle®

  An immunotherapy for equine endometritis. It is compatible with conventional treatments and is safe with natural breeding or AI. Sold in Canada, USA, Australia, New Zealand and UAE.

1. 1Novavive Inc. : NovaVive Inc.novavive.ca
2. 2Novavive Inc. : Our Companynovavive.ca
3. 3Novavive Inc. : Productsnovavive.ca
4. 4NovaVive Inc. (Canada) - Wikidatawikidata.org